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All patients with Diabetes Mellitus (DM) receive insulin therapy. In this study, we evaluated the efficacy, 
safety and tolerability of human insulin and insulin analogues. We performed a systematic review of 
the literature and a meta-analysis according to the Cochrane Collaboration methodology. In the absence 
of clinical studies comparing insulins, we performed a mixed treatment comparison to establish the 
differences between the active treatments. We included studies published from 1995 to 2010. HbA1c 
results, episodes of hypoglycemia and nocturnal hypoglycemia data were extracted and analyzed. 
Thirty-five randomized clinical trials were selected after examining the abstract and a full text review. 
These studies included 4,206 patients who received long-acting insulin analogues and 5,733 patients 
who received short-acting insulin analogues. Pooled data regarding efficacy indicated no significant 
differences in HbA1c values between glargine or detemir (once daily) and NPH insulin. However, a 
twice-daily dose of detemir produced differences in HbA1c values that favored detemir (-0.14% [95% 
CI: -0.21 to -0.08]; p<0.0001; I2=0%). Direct and indirect comparisons are consistent and show that 
there were no significant differences between human insulin and insulin analogues in efficacy or safety. 
Our results indicate that long- and short-acting insulin analogues offer few clinical advantages over 
conventional human insulin.
Uniterms: Insulins/meta-analysis. Diabetes mellitus/type 1. Insulin/treatment efficacy. Insulin/safety use.
Todos os pacientes com Diabetes Mellitus (DM) tipo 1 recebem insulina. Neste estudo, avaliaram-se 
eficácia, segurança e tolerabilidade de insulinas humanas e análogas. Realizou-se uma revisão sistemática 
e meta-análise, de acordo com o preconizado pela Colaboração Cochrane. Na ausência de estudos clínicos 
comparando insulinas entre si, realizaram-se meta-análises de comparações indiretas a fim de estabelecer 
diferenças entre tratamentos ativos. Incluíram-se estudos de 1995 a 2010. Resultados de HbA1c, 
episódios de hipoglicemia e hipoglicemia noturna foram extraídos e analisados. Após leitura de resumos 
e, posteriormente, de artigos na íntegra, selecionaram-se 35 ensaios clínicos randomizados, totalizando 
4206 pacientes utilizando insulina análoga de longa duração e 5733 pacientes insulina análoga de curta 
duração. Os resultados não demonstraram diferença estatisticamente significativa para redução de HbA1c 
entre glargina e detemir (uma vez ao dia) comparados a NPH. No entanto, insulina detemir utilizada 
duas vezes ao dia reduz a HbA1c (-0.14% [95% CI: -0.21 to -0.08]; p<0.0001; I2=0%). Comparações 
diretas e indiretas indicam que não existem diferenças significativas na médica de redução de HbA1c, 
independente da posologia de detemir, sendo estes resultados de eficácia e segurança consistentes. Os 
resultados indicam que insulinas análogas de longa ou curta duração apresentam pequenas vantagens, 
quando comparadas às insulinas tradicionais. Ademais, não existem diferenças entre eficácia e segurança 
quando comparamos insulinas análogas entre si.
Unitermos: Insulinas/meta-análise. Diabetes mellitus tipo 1. Insulina/eficácia. Insulina/segurança no uso.
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INTRODUCTION
Diabetes mellitus is associated with serious long-term 
complications and premature death (Singh et al., 2009). The 
Diabetes Control and Complications Trial (DCCT) and the 
UK Prospective Diabetes Study confirmed the benefits of 
improved glycemic control (DCCT, 1993; UKPDS, 1998). 
To implement intensive insulin therapy, a physiologic model 
of insulin replacement is applied to most patients with type 
1 diabetes mellitus (Pieber et al., 1995).
There are many good insulin formulations; however, 
metabolic control in many patients remains unsatisfactory 
(Plank et al., 2005).
For many years, the most commonly used type of 
insulin that provided a basal insulin supply was NPH 
(Neutral Protamine de Hagedorn); however, it has been 
shown to frequently result in nocturnal hypoglycemia 
due to unintended plasma insulin peaks (Rosenstock et 
al., 2005). Injection of regular human insulin does not 
replicate the postprandial endogenous secretion of insulin. 
Insulin analogues are modified forms of human insulin 
that have been developed to address this limitation (Singh 
et al., 2009). Since 2000, long-acting insulin analogues 
have been available. They are progressively replacing 
NPH insulin as the preferred form of basal insulin for type 
1 diabetes because of their favorable pharmacokinetics 
and pharmacodynamics, namely a less pronounced 
peak concentration and longer duration of action, which 
results in lower HbA1c levels and fewer episodes of 
hypoglycemia (Bolli et al., 2009a).
Unmodified human insulin hardly mimics the 
physiologic post-prandial insulin peak of non-diabetic 
people because there is a high tendency for it to 
aggregate as a hexamer at the injection site. Short-acting 
insulin analogues have reduced tendencies toward 
oligomerization, which allows them to be more quickly 
absorbed into the blood; as a consequence, they have faster 
onsets of action (Plank et al., 2005).
Numerous clinical trials have demonstrated the 
pharmacokinetic advantages of insulin analogues. 
However, a recent meta-analysis suggested that the rapid-
acting analogues provide only small advantages in terms of 
HbA1c (glycated hemoglobin or glycosylated hemoglobin) 
reductions and no advantages for hypoglycemia compared 
with unmodified human insulin (Gough, 2007). Although 
insulin analogues are commonly prescribed for the 
management of diabetes mellitus, there is uncertainty 
regarding their optimal use (Singh et al., 2009).
Systematic reviews of insulin analogues have been 
published previously (Brunelle et al., 1998; Siebenhofer A 
et al., 2004; Warren et al., 2004; Plank et al., 2005; Gough, 
2007; Monami et al., 2009; Singh et al., 2009). However, 
through our comprehensive search of the literature, we 
did not encounter any reviews delving into the efficacy, 
safety and tolerability of both short- and long-acting 
insulin analogues for the management of type 1 diabetes 
in adults. Within this context, the aim of this work was to 
evaluate these characteristics of short- and long-acting 
insulin analogues in comparison with the conventional 
human insulins.
METHODS
We performed a systematic review of the literature 
and a meta-analysis that compared the efficacy and 
safety of various long-acting insulin analogues, Neutral 
Protamine Hagedorn (NPH) and regular human insulin 
in type 1 diabetic adults (≥ 18 years). All studies used the 
same long-acting insulin for both treatments.
A systematic review of the literature was conducted 
in accordance with the methodology of the Cochrane 
Collaboration guidelines (Higgins et al., 2009). We 
performed a comprehensive search for randomized 
controlled trials using several combinations of keywords, 
including “glargine,” “lantus,” “detemir,” “levemir,” 
“aspart,” “novorapid,” “lispro,” “humalog,” “glulisine,” 
“apidra,” “type 1 diabetes,” “insulin-dependent diabetes” 
and “random,”* in the following databases: Scopus, 
Medline, Cochrane Library, Lilacs and International 
Pharmaceutical Abstracts (IPA). The literature search was 
supplemented with a hand search of references and other 
systematic reviews that have already been published. The 
search included studies performed between January 1995 
and December 2010 without language restriction. 
Selection and quality assessment of trials
Two reviewers (A.S. and R.V.) independently 
selected the studies initially by reviewing the titles and 
abstracts. These studies included exclusively double-
blinded randomized controlled trials (RCTs) of adult 
patients with established type 1 diabetes who received a 
long-acting insulin analogue (glargine or detemir), a short-
acting insulin analog (aspart, lispro or glulisine), NPH 
insulin (either alone or in combination with rapid-acting 
human insulin [regular]) or insulin analogues (lispro or 
aspart) for at least 4 weeks. We included detemir with a 
treatment regimen of once- or twice-daily. We excluded 
studies that used a crossover methodology.
Data extraction was performed by two independent 
authors (A.S. and C.C.) in accordance with the 
recommendations of the Cochrane Handbook for 
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Systematic Reviews of Interventions (Higgins et al., 
2009). Extracted data included study design, baseline 
characteristics, health intervention, drug regimen, 
concomitant treatments and outcomes. Any disagreement 
in data collection was resolved through consensus and 
with a third reviewer (R.V.) when necessary. The quality 
of each trial was evaluated using a method assessment tool 
published by Jadad et al. (1996).
Outcomes
Two major outcomes were obtained: efficacy, 
defined as a change (%) in HbA1c concentration at the end 
of the study, and safety, including overall hypoglycemia 
episodes and nocturnal hypoglycemia episodes, as defined 
by the number of patients with at least one episode during 
the study for long-acting insulin or the number of patients 
with at least one episode during a month for short-acting 
insulin.
Statistical analyses
The efficacy results are described as the mean 
difference (MD) with an associated 95% confidence 
interval (CI) for the HbA1c changes at the end of the 
studies. For the safety results (hypoglycemia) and 
withdrawals (because of adverse events or a lack of 
efficacy), the odds ratio (OR) method was used with the 
associated 95% CI of the event rates.
The data of the included studies were pooled 
across the trials using the random effect model (inverse 
variance method). Heterogeneity was evaluated by the 
inconsistency index (I2). Values of I2 lower than 25% were 
considered low heterogeneity, whereas values of 25-50% 
were considered moderate to high heterogeneity. In meta-
analyses that showed I2>50% (high heterogeneity), several 
sensitivity analyses were performed to determine whether 
the study characteristics (including low methodological 
quality) and statistical methods could have influenced 
the results.
When it was not possible to perform meta-analyses 
of direct treatment comparisons, we used indirect 
comparisons to evaluate the relative efficacy between 
insulin analogues. Indirect treatment comparisons in meta-
analyses can be analyzed by various methods according 
to the different networks applied, including star, ladder, 
closed-loop and partially closed-loop designs (Wells, 
2009). We used the star design, as described by Bucher 
et al. (Bucher; Guyatt; Griffith Le; Walter, 1997), and 
adjusted the relative efficacy by the level of response to a 
common denominator (NPH or regular insulin).
FIGURE 1 - Flowchart of the selection of randomized controlled 
trials included in our systematic review of long- and short-acting 
insulin analogues.
Stat ist ical  analyses were conducted using 
the software Review Manager V.5.0 for Windows 
(Copenhagen - Denmark: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2011) and the Indirect 
Treatment Comparison Software Application by the 
ADDIS (Aggregate Data Drug Information System) V.1.6 
(Groningen – Netherlands: University of Groningen, 
2012). A p value less than 0.05 was considered to be 
statistically significant.
RESULTS AND DISCUSSION
Systematic review of the literature
We initially identified 635 citations for glargine 
vs. NPH, 416 citations for detemir vs. NPH and 187 
citations for glargine and detemir, of which 601, 397 and 
183, respectively, were excluded on the basis of the title 
or abstract. Two independent reviewers evaluated the 
remaining articles (see Figure 1).
The remaining 16 articles for long-acting insulin 
analogues (glargine vs. NPH, 7; detemir vs. NPH, 7; 
glargine vs detemir, 2) were included in our meta-analysis 
A. C. C. Sanches, C. J. Correr, R. Venson, P. R. Gonçalves, M. M. Garcia, M. S. Piantavini, R. Pontarolo504
(Garg et al., 1995; Anderson Jr. et al., 1997; Ciofetta et al., 
1999; Home, 2000; Raskin, Guthrie, et al., 2000; Raskin, 
Klaff et al., 2000; Ratner et al., 2000; Rosenstock et al., 
2000; Bode, Strange, 2001; Tamas et al., 2001; Bode et al., 
2002; Devries et al., 2003; Vague et al., 2003; Hermansen 
et al., 2004; Porcellati et al., 2004; Russell-Jones et al., 
2004; Home et al., 2004; De Leeuw et al., 2005; Fulcher 
et al., 2005; Home et al., 2005; Pieber et al., 2005; Home 
et al., 2006; Pieber et al., 2007; Bartley et al., 2008; Heller 
et al., 2009; Bolli et al., 2009 b).
When we combined all of the studies, we counted 
5,733 patients who received a short-acting insulin analog 
(aspart, lispro or glulisine). For lispro vs. regular, there 
were 954 patients; aspart vs. regular, 681; glulisine vs. 
regular, 240; glulisine vs. lispro, 140; glulisine vs. aspart, 
112; lispro vs. aspart, 696. For all of the participants, 
the mean age was 39.2 years, and the mean body mass 
index (BMI) was 24.8. The number of patients in each 
study ranged from 57 to 747. The durations of the trials 
ranged from 7 to 64 weeks. The studies that examined the 
effects of long-acting insulin included 4,771 patients who 
received long-acting or NPH insulin. For the participants 
in these studies, the mean BMI was 24.9. The number of 
patients in each study ranged from 57 to 747. The trials 
included in the current meta-analysis had a mean duration 
of treatment of 26 weeks for glargine and 25 weeks for 
detemir. The durations of the trials ranged from 4 weeks 
to 12 months.
Efficacy of long- and short-acting insulin 
analogues
Forest plots showing the mean difference (MD) 
based on the change in HbA1c values at the end of the 
studies in adults with type 1 diabetes receiving glargine 
or detemir versus NPH or aspart, lispro or glulisine versus 
regular insulin are represented in Figure 2.
Compared with NPH insulin, the use of insulin 
glargine did not result in significant differences in HbA1c 
values (MD: -0.04% [95% CI: -0.12 to 0.05]; p = 0.39). 
There was a moderate degree of heterogeneity (43%). 
Primary data for detemir, compared with NPH insulin, 
were pooled into two subgroups based on the treatment 
regimen of once- or twice-daily treatment. For the once-
a-day regimen, no statistically significant differences 
were found that favored one particular treatment (MD: 
-0.11% [95% CI: -0.32 to 0.11]; p = 0.34), but the results 
were inconsistent (I2 = 71%) because of the low number 
of studies. For the twice-a-day regimen, the difference 
in HbA1c values favored detemir (MD: -0.14% [95% 
CI: -0.21 to -0.01]; p<0.0001; I2 = 0%). The overall 
result of the meta-analysis favored detemir because of 
the low heterogeneity values. We found no significant 
differences in the mean change in HbA1c values when 
we directly compared glargine and detemir (2 studies). 
The MD, independent of the detemir treatment regimen, 
was -0.07% (95% CI: -0.19 to 0.06; p = 0.31; I2 = 0%). 
It was not possible to perform a meta-analysis separately 
comparing once-daily or twice-daily glargine and detemir. 
A mixed treatment comparison of glargine and detemir 
(once- or twice-daily), adjusted for the level of response to 
NPH insulin, showed no significant difference in the mean 
change in the HbA1c value. The MD observed for both 
detemir regimens was -0.12% [95% CI: -0.03 to 0.20]. 
We found that aspart is more effective than regular insulin 
(MD: -0.13 [95% CI: -0.17 to -0.09]; p < 0.00001%), with 
little variability between studies, as demonstrated by a 
heterogeneity value of 0%. While inpatients treated with 
insulin lispro did not differ significantly (p = 0.36, MD: 
-0.08 [95% CI: -0.24 to 0.8]), the absence of heterogeneity 
FIGURE 2 - Forest plots showing the MD based on the HbA1c changes at the end of the studies in adults with type 1 diabetes using 
the inverse variance method (random effect model).
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TABLE I - HbA1C reductions, SD and p values for the following comparisons: glulisine vs. regular insulin, glulisine vs. lispro and 
aspart vs. lispro
Comparison Author/year Reduction HbA1C±SD p value
Glulisine vs. Regular Garg, 2005 Glulisine Regular P=0.670
*AM 
-0.26±0.65 -0.13±0.66
**BM 
-0.11±0.65 -0.13±0.66
Glulisine vs. Lispro Kawamori, 2009 Glulisine Regular NA 
0.10±0,71 0.03±0.58
Aspart vs. Lispro Bode, 2002 Aspart Lispro NA
0.00±0.51 0.18±0.84
* AF: after meal; ** BM: before meal; NA: not available
(0%) was demonstrated by the sensitivity, robustness and 
regularity among the studies. The network of evidence 
surrounding comparisons of glargine, detemir and NPH 
insulin showed that there were no significant differences 
among treatments (glargine vs. NPH [-0.07 (-0.16; 0.03)], 
detemir vs. NPH [-0.07 (-0.16; 0.02)] and glargine vs. 
detemir [-0.00 (-0.11; 0.11)]). The rank of probability to 
choose long-acting insulin shows that NPH is first (87%), 
detemir is second (53%) and glargine is third (46%). The 
potential reduction scale factor was 1, and these results 
are consistent. 
In our systematic review, we only found one article 
comparing insulin glulisine versus regular insulin and one 
clinical trial comparing insulin aspart, glulisine and lispro. 
Therefore, we could not perform a meta-analysis of these 
comparisons. The results for HbA1c reductions in these 
studies are presented in Table I.
We found small differences between treatments 
when we searched the various studies, and direct meta-
analyses were performed to contribute to the analysis of 
this outcome.
HbA1C reductions were analyzed using the ADDIS 
software, which performs network meta-analyses and 
portrays results graphically, as shown in Figures 3 A and B.
 Among human rapid-acting insulin options, regular 
insulin is most likely to be the first choice for the treatment 
of type 1 DM, followed by the insulin analog glulisine, 
then lispro and finally aspart. Our results, which show 
small differences in the ability of similar rapid-acting 
insulin analogues and regular human insulin to lower 
FIGURE 3 – The probability that long- (A) or rapid-acting (B) insulin analogues are the best choice for patients with type 1 diabetes 
mellitus. Rank 1 represents the insulin analog most likely to be the first choice for treatment of type 1 diabetes mellitus.
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HbA1C values, are in agreement with those that have been 
found by other authors (Jansson et al., 1998; Siebenhofer 
et al., 2004; Plank et al., 2005; Forst, Pfützner, 2007).
The results of the long- and short-acting insulin 
analogues are consistent, and direct and indirect 
comparisons did not reveal significant differences among 
human insulin and insulin analogues with regard to their 
ability to reduce HbA1C values. Therefore, although 
there is a ranking system that can be used to choose the 
best option for insulin therapy, the differences in efficacy 
between them are small. These data are consistent with 
direct measurements that have already been published.
Safety of long-acting insulin analogues 
The results detailing the safety of glargine, detemir 
and NPH insulin are shown in Figure 4 A. Figure 4 B 
shows the safety results of short-acting (lispro, aspart and 
regular) insulin types.
The hypoglycemia results were inconsistent for 
both insulin analogues (high I2). For glargine and NPH, 
the mean percentages of participants reporting any 
hypoglycemia episode (74.4 vs. 74.1%) were not different. 
The hypothetical exclusion of any trial did not change 
the outcomes. For detemir and NPH, we found similar 
results; the mean percentages of participants reporting any 
hypoglycemia episode were 79.2 and 81.5%, respectively. 
The exclusion of one study (39) reduced the heterogeneity 
to 52% without significant changes to the results. This 
difference likely results from the high doses of detemir 
(0.83 UI/kg/day) and NPH insulin (0.44 UI/kg/day) in 
the study by Vague et al. in relation to the doses used in 
the other studies (0.31 to 0.44 UI/kg/day for detemir and 
0.32 to 0.36 UI/kg/day for NPH). Safety, as measured by 
the number of patients with at least one hypoglycemic 
episode per month, was analyzed for short-acting insulin 
analogues. We observed no significant differences between 
insulin aspart and regular insulin, and the heterogeneity 
was 0%. The same result was found when we compared 
insulin lispro with regular insulin; however, the clinical 
trial by Ciofetta et al. (Ciofetta et al., 1999) included only 
a small number of patients (n = 8) in both groups, thereby 
causing greater variability in the results. This variability 
resulted in moderate heterogeneity (38%). Insulin glulisine 
compared with regular insulin was also not significantly 
different; however, for insulin glulisine, the meta-analysis 
was not performed because only one clinical trial was 
found with the correct inclusion criteria. A similar situation 
occurred when we compared insulin lispro with glulisine 
(3.93 vs. 3.86; p = 0.1642). In the only instance where 
both insulin aspart and lispro were compared, the authors 
(Bode et al., 2002) confirmed that hypoglycemic episodes 
per month were not significantly different between the 
treatments; however, there was less of these episodes for 
the group treated with insulin aspart (3.9 ± 4.2) compared 
with insulin lispro (4.4 ± 5.6) or regular insulin (4.9 ± 4.6).
CONCLUSIONS
Long- and short-acting insulins are used to 
compensate for a lack of insulin secretion in patients 
with type 1 diabetes. These patients use multiple daily 
injections or continuous subcutaneous insulin infusions to 
mimic the mealtime rapid-acting or basal insulin normally 
secreted by the pancreas (Bolli et al., 2009 a).
There were no significant differences in the changes 
in HbA1c values for glargine and detemir (once-daily) 
compared with NPH insulin and glargine versus detemir. 
Moreover, for the twice-daily detemir regimen, the 
differences in HbA1c values favor detemir over NPH 
insulin. With regard to indirect comparisons of detemir and 
glargine, the two primary studies combined the efficacy 
FIGURE 4 - Odds ratio for hypoglycemia (patients with any episode during the study) with insulin analogues, where A contains the 
meta-analysis of the safety of long-acting insulins and B contains the meta-analysis of the safety of short-acting insulin analogues. 
Legend: Glar, glargine; Det, Detemir; NPH, Human Insulin NPH.
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data of once- or twice-daily detemir regimens and thus 
did not allow a separate meta-analysis of both regimens. 
In these cases, mixed treatment comparisons indicated no 
significant differences in the efficacy of once- or twice-daily 
detemir compared with once-daily glargine. Aspart is more 
effective when compared with regular insulin, but lispro and 
glulisine, which are also short-acting insulin analogues, are 
not more effective than human short-acting insulin.
Safety data based on clinical trials comparing glargine 
and detemir were similar with regard to patients with 
any hypoglycemia episode (56.1% vs. 37.8%; p = 0.06, 
respectively), without significant differences calculated 
by the risk ratio. There were no statistically significant 
differences among short-acting insulin treatments. In 
summary, these results indicate that there are only small 
differences in glycemic control and safety among human 
and insulin analogues (long- and short-acting).
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